Company: IMNN
Filing Date: 2025-12-31
Form Type: 424B5
Source: 0001493152-25-029712
Chunk: 11

Company: Imunon, Inc.
Filing Date: 2025-12-31
Form: 424B5
Chunk 11
---
 and working capital. Pending the application of the net proceeds, we intend to invest the net proceeds in short-term, investment grade, interest-bearing securities.

As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering, if any. As a result, our management will have broad discretion regarding the timing and application of the net proceeds from this offering.

| S-7 |

<div align='center'>DIVIDEND POLICY</div>

We have never declared or paid cash dividends on our common stock. We currently intend to retain our future earnings, if any, for use in our business and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs and plans for expansion.

| S-8 |

<div align='center'>DILUTION</div>

If you invest in our common stock, your interest will be diluted to the extent of the difference between the price per share of our common stock you pay in this offering and the as adjusted net tangible book value per share of our common stock immediately after this offering.

As of September 30, 2025, our historical net tangible book value was $4.1 million, or $1.41 per share of common stock. Historical net tangible book value per share represents the amount of our total tangible assets less total liabilities, divided by the number of shares of common stock outstanding as of September 30, 2025.

After giving effect to the sale of our common stock and Pre-funded Warrants and accompanying Warrants to purchase common stock in the aggregate amount of approximately $7.0 million at a combined offering price of $3.61 per Share and Warrant (and $3.6099 per Pre-funded Warrant and Warrant), and after deducting commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of September 30, 2025 would have been $10.4 million, or $2.14 per share of common stock. This amount represents an immediate increase in net tangible book value of $0.73 per share to our existing stockholders and an immediate dilution in net tangible book value of approximately $1.47 per share to new investors in this offering.

The following table illustrates this calculation on a per share basis.

| Combined offering price per Share and